ROM Utrecht Region
VC Fund
Utrecht, The Netherlands
ROM Utrecht Region is a VC fund in Utrecht focused on Medical and Health Care. ROM Utrecht Region invest in digital, health, and sustainability businesses in the Utrecht region, the Netherlands
- Total investments:
- 27
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries ROM Utrecht Region invests in
Stages ROM Utrecht Region invests in
Countries ROM Utrecht Region invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adinda Woelderink
|
|||
Jeffrey Williams
|
|||
|
Joyce Houterman
|
|||
2 more contacts available
Investment Focus
Industry
- Medical 4 (15%)
- Health Care 4 (15%)
- Biotechnology 4 (15%)
- Medical Device 3 (11%)
- Artificial Intelligence 3 (11%)
Stage
- Seed 11 (41%)
- Venture - Series Unknown 4 (15%)
- Series A 3 (11%)
- Pre-Seed 2 (7%)
- Series B 2 (7%)
Country
- The Netherlands 21 (78%)
- United States 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Adinda Woelderink
Executive
|
Executive | Total investments: 3 | Find email | |
|
Jeffrey Williams
Sr. Investment Manager
|
Sr. Investment Manager | Total investments: 3 | Find email | |
|
Joyce Houterman
Investment Manager
|
Investment Manager | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Laigo Bio
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | |
Vitestro
|
Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | |
ViCentra
|
ViCentra, they like to keep things simple.ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things.Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customerexperiences.From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people. | $13M / Series D / Jan 08, 2026 | |
|
Laigo Bio
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | |
Zympler
|
Simpl.energy provides solutions for improving the utilization of available grid capacity. | $1.8M / Seed / Sep 05, 2025 | |
Basetime
|
Geodetic Measurement, Precision Monitoring | Jul 09, 2025 | |
Sygno
|
Fighting financial crime isn’t fair. Both your hands are tied. Criminals keep changing the game, while you have to play by the rules. Lots of rules. Meanwhile your business keeps accelerating. To keep up and comply at the same time means adding layer upon layer of complexity. Leading to higher costs and ever more cumbersome processes, burdeningyour clients. Clearly, this way of thinking isn’t working, so shouldn’t we rethink the problem?Here’s what we think. Financial criminals are always looking for loopholes to stay ahead of being detected. Normal people aren’t. So why base your approach on exceptions and not on the rule? When you focus on regular customer behavior, the anomalies clearly stick out.This may sound simple. It is also very effective. You drastically reduce false positives and increase true positives as previously undetected patterns now become visible. So you can identify the right cases faster, at lower cost.This is how it works. Our automated machine learning technology generates detection models. Based on your own raw data and regulatory requirements. It deploys these models in your transaction monitoring system of choice. Because the value isn’t in the system, it’s in the detection models running on it. They enhance the monitoring system to better identify known and yet unknown financial crime. This makes everyone’s lives so much easier. Your case analysts can now spend their time on meaningful investigations. Your data scientists can get rid of their backlog and focus on other, more bank-specific risks. Your compliance team can explain these transparent models to regulators. Think white box, not black box.At Sygno we approach financial crime from a clear-cut premise: most of your customers are not criminals. By looking at it this way, we make transaction monitoring more manageable and effective. So you can catch crooks, comply and be in full control. Why lose any more sleep over it?Sygno Know good, catch bad | Venture - Series Unknown / Jun 24, 2025 | |
Rival Foods
|
Rival Foods specializes in food production and manufacturing and offers plant-based culinary whole-cuts. The company brings culinary plant-based alternatives to traditional protein sources such as meat and fish not compromising on taste and experience. | $11.5M / Series B / Jun 18, 2025 | |
CryoCloud
|
CryoCloud is a biotech firm offering cloud-based image analysis for protein structure determination. | $2.3M / Seed / May 06, 2025 | |
PAKT
|
PAKT specializes in the industrial sorting and washing of glass packaging, offering large-scale cleaning services to support the reuse of glass containers. With a focus on sustainability, PAKT aims to contribute to a world without waste by promoting the circular economy. The company's services are designed to meet the needs of businesseslooking to reduce their environmental impact through the professional cleaning and reuse of glass pots and bottles. PAKT's approach combines technological innovation with a commitment to environmental responsibility, providing a solution that supports both the planet and the packaging needs of its clients. | Grant / Apr 01, 2025 | |
| See all 27 investments → | |||
Co-Investors
Utrecht Health Seed Fund
4 deals together
Curie Capital
3 deals together
Angelini Ventures
2 deals together
ARGOBIO
2 deals together
Cancer Research Horizons
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does ROM Utrecht Region invest in?
ROM Utrecht Region invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 27 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ROM Utrecht Region?
Public channels for ROM Utrecht Region include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ROM Utrecht Region?
The team at ROM Utrecht Region includes Adinda Woelderink (Executive), Jeffrey Williams (Sr. Investment Manager) and Joyce Houterman (Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
